All In Biotech

Drug Trial Radar · NCT07815301

Gradual Tapering or Discontinuation of Beta-Blockers After Stabilization With Mavacamten Therapy

Feasibility and Safety of Sequential Tapering and Discontinuation of Beta-blockers in Patients With Obstructive Hypertrophic Cardiomyopathy After Achieving Hemodynamic Targets With Mavacamten: a Multicenter, Randomized, Open-label, Parallel-group, Non-inferiority Trial (STEP-oHCM)

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 286 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

286

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
First Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter, randomized, open-label, parallel-group, non-inferiority trial will evaluate whether sequential tapering and discontinuation of beta-blockers is non-inferior to maintenance of the baseline stable beta-blocker dose in adult patients with obstructive hypertrophic cardiomyopathy (oHCM) who have achieved predefined clinical and hemodynamic stability during mavacamten treatment. Eligible participants will be randomly assigned in a 1:1 ratio to a sequential tapering and discontinuation group or a baseline stable-dose maintenance group. In the tapering group, the beta-blocker dose will be reduced stepwise approximately every 4 weeks, with complete discontinuation planned at Week 12 if predefined safety and stability criteria are met. Participants will be followed through Week 24. The primary objective is to compare the proportion of participants who maintain clinical and hemodynamic stability without protocol-defined treatment failure through Week 24. The feasibility and safety of complete beta-blocker discontinuation will also be evaluated.

Conditions

  • Obstructive Hypertrophic Cardiomyopathy (oHCM)

Interventions

  • Beta-Blocker Sequential Tapering and DiscontinuationDrug

    Participants will undergo sequential tapering of their baseline beta-blocker therapy. The daily beta-blocker dose will be reduced approximately every 4 weeks following a planned dose pathway of approximately 100%, 75%, 50%, 25%, and 0% of the randomization baseline daily dose. Complete discontinuation is planned at Week 12 if predefined clinical, hemodynamic, and safety criteria are met. Dose reduction may be paused or delayed, and dose rollback or rescue treatment may be implemented according to protocol-defined criteria.

  • Beta-Blocker Baseline Stable-Dose MaintenanceDrug

    Participants will continue the beta-blocker type, dosing frequency, and daily dose that were stable at randomization throughout the 24-week randomized follow-up period, unless dose modification is clinically required because of efficacy or safety concerns according to the study protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Week 24 Clinical and Hemodynamic Strategy Success RateTime frame: From randomization through Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.